Patents by Inventor Darwin J. Prockop

Darwin J. Prockop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150374791
    Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.
    Type: Application
    Filed: July 1, 2015
    Publication date: December 31, 2015
    Inventors: Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
  • Publication number: 20150299302
    Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.
    Type: Application
    Filed: May 20, 2015
    Publication date: October 22, 2015
    Inventors: Darwin J. Prockop, Joo Youn Oh, Barry Berkowitz
  • Publication number: 20150283180
    Abstract: A method of preventing or treating rejection of a transplanted cell, tissue, or organ in an animal by administering to the animal a composition comprising an effective amount of mesenchymal stem cells and/or at least one anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof.
    Type: Application
    Filed: November 1, 2012
    Publication date: October 8, 2015
    Inventors: JiMin Yu, Darwin J. Prockop, Joo Youn Oh, RyangHwa Lee
  • Publication number: 20150272992
    Abstract: A method of treating a tumor in an animal by administering to the animal mesenchymal stem cells that have been contacted with a stimulating, or activating agent, such as TNF-a, that stimulates the mesenchymal stem cells to express increased amounts of at least one agent, such as TRAIL and/or DKK-3, that inhibits, prevents, or destroys the growth of tumors. The stimulated, or activated mesenchymal stem cells may be administered in combination with at least one chemotherapeutic agent, such as doxorubicin.
    Type: Application
    Filed: October 17, 2013
    Publication date: October 1, 2015
    Inventors: Darwin J. Prockop, Ryang Hwa Lee, Nara Yoon, John Reneau, Barry Berkowitz
  • Publication number: 20150265675
    Abstract: A method of treating brain injury or brain trauma in an animal by administering to an animal TSG-6 protein or a biologically active fragment, derivative, or analogue thereof.
    Type: Application
    Filed: October 17, 2013
    Publication date: September 24, 2015
    Inventors: Darwin J. Prockop, Dong-Ki Kim, Jun Watanabe, Ashok Shetty, Bharathi Hattiangady, Jessica Foraker, Barry Berkowitz
  • Patent number: 9090704
    Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: July 28, 2015
    Assignees: Scott & White Healthcare, The Texas A&M University System
    Inventors: Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
  • Patent number: 9062103
    Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: June 23, 2015
    Assignees: The Texas A&M University System, Temple Therapeutics, Inc., Scott & White Healthcare
    Inventors: Darwin J. Prockop, Joo Youn Oh, Barry Berkowitz, Gavin W. Roddy, Robert Rosa
  • Publication number: 20150119343
    Abstract: A method of producing a protein or polypeptide, such as, for example, TSG-6 protein, or a biologically active fragment, derivative or analogue thereof, by introducing into mammalian cells a polynucleotide encoding the biologically active protein or polypeptide or biologically active fragment, derivative, or analogue thereof. The cells then are suspended in a protein-free medium that includes at least one agent that suppresses production of hyaluronic acid, hyaluronan, or a salt thereof by the cells. The cells are cultured for a time sufficient to express the biologically active protein or polypeptide or biologically active fragment, derivative or analogue thereof. The biologically active protein or polypeptide, or fragment, derivative, or analogue thereof then is recovered from the cells, such as, for example, by recovering the protein or polypeptide secreted by the cells from the cell culture medium.
    Type: Application
    Filed: November 1, 2012
    Publication date: April 30, 2015
    Inventors: Darwin J. Prockop, Jun Watanabe, Dong-Ki Kim, RyangHwa Lee, Hosoon Choi
  • Publication number: 20140308295
    Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 16, 2014
    Inventors: Darwin J. Prockop, Joo Youn Oh, Barry Berkowitz
  • Publication number: 20140286914
    Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.
    Type: Application
    Filed: May 22, 2014
    Publication date: September 25, 2014
    Applicants: Scott & White Healthcare, The Texas A&M University System
    Inventors: Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
  • Patent number: 8785395
    Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: July 22, 2014
    Assignees: The Texas A & M University System, Temple Therapeutics, Inc.
    Inventors: Darwin J. Prockop, Joo Youn Oh, Gavin W. Roddy, Robert Rosa, Barry A. Berkowitz
  • Patent number: 8759298
    Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: June 24, 2014
    Assignees: Scott & White Healthcare, The Texas A&M University System
    Inventors: Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
  • Publication number: 20130302889
    Abstract: The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine. Once induced to differentiate into neuronal cells, the cells can be used for cell therapy, gene therapy, or both, for treatment of diseases, disorders, or conditions of the central nervous system.
    Type: Application
    Filed: July 11, 2013
    Publication date: November 14, 2013
    Inventors: Ira B. Black, Dale L. Woodbury, Darwin J. Prockop, Emily Schwarz
  • Patent number: 8486698
    Abstract: The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine. Once induced to differentiate into neuronal cells, the cells can be used for cell therapy, gene therapy, or both, for treatment of diseases, disorders, or conditions of the central nervous system.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: July 16, 2013
    Assignees: University of Medicine and Dentistry of New Jersey, Philadelphia Health and Education Corporation
    Inventors: Ira B. Black, Dale L. Woodbury, Darwin J. Prockop, Emily Schwarz
  • Publication number: 20130143814
    Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.
    Type: Application
    Filed: July 16, 2012
    Publication date: June 6, 2013
    Inventors: Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
  • Publication number: 20130039924
    Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.
    Type: Application
    Filed: May 3, 2011
    Publication date: February 14, 2013
    Inventors: Darwin J. Prockop, Yoo Youn Oh, Gavin W. Roddy, Robert Rosa, Barry A. Berkowitz
  • Publication number: 20120219572
    Abstract: The present invention encompasses methods and compositions for reducing inflammation in a mammal. The invention includes a population of mesenchimal stromal cells that possess anti-inflammatory, anti-apoptolic, immune modulatory, and anti-tumorigenic properties.
    Type: Application
    Filed: November 12, 2010
    Publication date: August 30, 2012
    Inventors: Darwin J. Prockop, Thomas W. Bartosh, JR., Joni Ylostalo
  • Publication number: 20120213752
    Abstract: Isolated stromal cells, containers comprising isolated stromal cells transfected with exogenous DNA, and methods of treating patients suffering from diseases characterized by a bone cartilage or lung defect are disclosed. The methods comprise obtaining a bone marrow sample from a donor, isolating stromal cells from the sample, and administering the isolated stromal cells to the patient.
    Type: Application
    Filed: February 23, 2012
    Publication date: August 23, 2012
    Inventors: Darwin J. Prockop, Ruth F. Pereira, Dennis B. Leeper, Michael D. O'Hara, Joseph Kulkosky, Donald Phinney, Alexey Laptev, Jose Caro
  • Publication number: 20120027729
    Abstract: Transplantation of multipotent stromal cells (MSCs) into diabetic mice lowers blood sugar, increases blood insulin levels, increases the number and size of islets, and improves renal pathology. Accordingly, the invention provides methods for treating or preventing diabetes by administering isolated MSCs. The invention also provides methods for treating or preventing complications which arise from diabetes, including diabetic nephropathy, by transplanting isolated MSCs.
    Type: Application
    Filed: April 27, 2007
    Publication date: February 2, 2012
    Applicant: Tulane University Health Sciences Center
    Inventors: Darwin J. Prockop, Ryang Hwa Lee, Min Jeong Seo
  • Publication number: 20110223138
    Abstract: The invention includes a purified population of mesenchymal stromal cells that have been cultured under conditions, such as having been contacted with an apoptotic cell, to express increased levels of at least one anti-apoptotic protein. Such mesenchymal stem cells may be used to treat diseases, disorders, or conditions associated with apoptosis or with unresolved inflammation.
    Type: Application
    Filed: December 17, 2010
    Publication date: September 15, 2011
    Inventors: Darwin J. Prockop, Gregory J. Block, Shinya Ohkouchi, Hosoon Choi